• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

    5/5/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Revenue of $586.0 million, up 111% year-over-year in Q1 2025

    Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025

    Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025

    Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million

    Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.hims.com.

    "We're starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes," said Andrew Dudum, co-founder and CEO. "We're building a platform that puts the individual at the center of every decision and others are taking notice. Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world class providers. We believe this will strengthen our ecosystem and position us to curate a best-in-class offering that can reach tens of millions of people. This is the future of our platform, allowing a historically disjointed industry to reach more consumers, for the benefit of those consumers."

    Yemi Okupe, CFO, stated, "During the first quarter, our subscriber base grew to nearly 2.4 million, with over 1.4 million utilizing personalized solutions. Revenue increased 111% year-over-year as we continued to deliver access to more precise, personalized care at scale. This momentum, combined with our strong track record of execution, reinforces our confidence in driving sustained long-term growth across five core levers: deepening personalization, expanding into new specialties, elevating the subscriber experience with access to high quality follow up care, forging innovative partnerships, and entering new geographies. Investments across these priorities underpin our updated 2025 guidance as well as our new long-term targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030."

    Key Business Metrics

    (In Thousands, Except for Monthly Online Revenue per Average Subscriber, Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

     

    % Change

    Subscribers (end of period)

     

     

    2,366

     

     

    1,709

     

    38

    %

    Monthly Online Revenue per Average Subscriber

     

    $

    84

     

    $

    55

     

    53

    %

    Revenue

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

     

    % Change

    Online Revenue

     

    $

    576,361

     

    $

    267,761

     

    115

    %

    Wholesale Revenue

     

     

    9,649

     

     

    10,410

     

    (7

    )%

    Total revenue

     

    $

    586,010

     

    $

    278,171

     

    111

    %

    First Quarter 2025 Financial Highlights

    • Revenue was $586.0 million for the first quarter of 2025 compared to $278.2 million for the first quarter of 2024, an increase of 111% year-over-year.
    • Gross margin was 73% for the first quarter of 2025 compared to 82% for the first quarter of 2024.
    • Net income was $49.5 million for the first quarter of 2025 compared to $11.1 million for the first quarter of 2024.
    • Adjusted EBITDA was $91.1 million for the first quarter of 2025 compared to $32.3 million for the first quarter of 2024.
    • Net cash provided by operating activities was $109.1 million for the first quarter of 2025 compared to $25.8 million for the first quarter of 2024.
    • Free Cash Flow was $50.1 million for the first quarter of 2025 compared to $11.9 million for the first quarter of 2024.

    Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States ("U.S. GAAP"), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading "Non-GAAP Financial Measures".

    Financial Outlook

    Hims & Hers is providing the following guidance:

    For the second quarter 2025, we expect:

    • Revenue of $530 million to $550 million.
    • Adjusted EBITDA of $65 million to $75 million, reflecting an Adjusted EBITDA margin of 12% to 14%.

    For the full year 2025, we expect:

    • Revenue of $2.3 billion to $2.4 billion.
    • Adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%.

    2030 Financial Targets

    Hims & Hers has demonstrated a consistent track record of execution driven by the strength of its business model and operational excellence, which is fueling strong top line growth and Adjusted EBITDA profitability. Given its large market opportunity and growing customer demand, the Company is providing financial targets for the full year 2030, which include:

    • Revenue of at least $6.5 billion.
    • Adjusted EBITDA of at least $1.3 billion.

    The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

    Conference Call

    Hims & Hers will host a conference call to review the first quarter 2025 results on May 5, 2025, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

    For more information, please visit investors.hims.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believe," "estimate," "anticipate," "expect," "assume," "imply," "intend," "plan," "may," "will," "potential," "project," "predict," "continue," "could," "confident," "confidence," or "should," or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our 2025 and 2030 financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions, the success of our business model, our market opportunity, our ability to scale our business and expand internationally, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission").

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

    By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

    Key Business Metrics

    We continually and strategically review our key business metrics to ensure that they are helpful in managing or monitoring the performance of our business as it grows, which may result in changes in our key business metrics over time. As an example, our management primarily uses the Subscribers and Monthly Online Revenue per Average Subscriber metrics, as defined below, to manage and monitor the performance of our business. The Net Orders and AOV metrics have become less relevant for our business, and beginning with the three months ending March 31, 2025 we are no longer reporting them as key business metrics.

    "Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

    "Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

    "Subscribers" are customers who have one or more "Subscriptions" pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services.

    "Monthly Online Revenue per Average Subscriber" is defined as Online Revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. "Average Subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

    March 31, 2025

     

    December 31, 2024

     

     

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    273,736

     

     

    $

    220,584

     

    Short-term investments

     

    48,935

     

     

     

    79,667

     

    Inventory

     

    76,096

     

     

     

    64,427

     

    Prepaid expenses and other current assets

     

    48,197

     

     

     

    31,153

     

    Total current assets

     

    446,964

     

     

     

    395,831

     

    Restricted cash

     

    1,223

     

     

     

    856

     

    Goodwill

     

    117,753

     

     

     

    112,728

     

    Property, equipment, and software, net

     

    155,707

     

     

     

    82,083

     

    Intangible assets, net

     

    43,431

     

     

     

    43,410

     

    Operating lease right-of-use assets

     

    62,198

     

     

     

    10,881

     

    Deferred tax assets, net

     

    62,493

     

     

     

    61,603

     

    Other long-term assets

     

    1,942

     

     

     

    147

     

    Total assets

    $

    891,711

     

     

    $

    707,539

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    108,919

     

     

    $

    91,180

     

    Accrued liabilities

     

    56,942

     

     

     

    53,013

     

    Deferred revenue

     

    110,765

     

     

     

    75,285

     

    Operating lease liabilities

     

    3,736

     

     

     

    1,889

     

    Total current liabilities

     

    280,362

     

     

     

    221,367

     

    Operating lease liabilities

     

    59,648

     

     

     

    9,456

     

    Other long-term liabilities

     

    2,440

     

     

     

    —

     

    Total liabilities

     

    342,450

     

     

     

    230,823

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 215,206,274 and 212,459,586 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2025 and December 31, 2024

     

    22

     

     

     

    22

     

    Additional paid-in capital

     

    742,055

     

     

     

    719,155

     

    Accumulated other comprehensive loss

     

    (164

    )

     

     

    (324

    )

    Accumulated deficit

     

    (192,652

    )

     

     

    (242,137

    )

    Total stockholders' equity

     

    549,261

     

     

     

    476,716

     

    Total liabilities and stockholders' equity

    $

    891,711

     

     

    $

    707,539

     

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

    Revenue

     

    $

    586,010

     

     

    $

    278,171

     

    Cost of revenue

     

     

    155,321

     

     

     

    49,076

     

    Gross profit

     

     

    430,689

     

     

     

    229,095

     

    Gross margin %

     

     

    73

    %

     

     

    82

    %

    Operating expenses:(1)

     

     

     

     

    Marketing

     

     

    231,235

     

     

     

    130,553

     

    Operations and support

     

     

    63,033

     

     

     

    38,747

     

    Technology and development

     

     

    29,914

     

     

     

    15,324

     

    General and administrative

     

     

    48,610

     

     

     

    34,568

     

    Total operating expenses

     

     

    372,792

     

     

     

    219,192

     

    Income from operations

     

     

    57,897

     

     

     

    9,903

     

    Other income and expense, net

     

     

    2,598

     

     

     

    2,500

     

    Income before income taxes

     

     

    60,495

     

     

     

    12,403

     

    Provision for income taxes

     

     

    (11,010

    )

     

     

    (1,275

    )

    Net income

     

     

    49,485

     

     

     

    11,128

     

    Other comprehensive income (loss)

     

     

    160

     

     

     

    (38

    )

    Total comprehensive income

     

    $

    49,645

     

     

    $

    11,090

     

     

     

     

     

     

    Net income per share attributable to common stockholders:

     

     

     

     

    Basic

     

    $

    0.22

     

     

    $

    0.05

     

    Diluted

     

    $

    0.20

     

     

    $

    0.05

     

    Weighted average shares outstanding:

     

     

     

     

    Basic

     

     

    221,989,327

     

     

     

    213,452,092

     

    Diluted

     

     

    246,610,232

     

     

     

    229,364,585

     

    ______________

    (1)

    Includes stock-based compensation expense as follows (in thousands):

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

    Marketing

     

    $

    2,774

     

     

    $

    1,904

     

    Operations and support

     

     

    3,006

     

     

    2,155

    Technology and development

     

     

    4,045

     

     

     

    2,205

     

    General and administrative

     

     

    15,033

     

     

     

    12,768

     

    Total stock-based compensation expense

     

    $

    24,858

     

     

    $

    19,032

     

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In Thousands, Unaudited)

     

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Operating activities

     

     

     

    Net income

    $

    49,485

     

     

    $

    11,128

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    8,276

     

     

     

    3,001

     

    Stock-based compensation

     

    24,858

     

     

     

    19,032

     

    Net accretion on securities

     

    (693

    )

     

     

    (1,077

    )

    Benefit for deferred taxes

     

    (890

    )

     

     

    (1

    )

    Non-cash operating lease cost

     

    1,905

     

     

     

    574

     

    Non-cash acquisition-related costs

     

    1,030

     

     

     

    —

     

    Non-cash other

     

    832

     

     

     

    484

     

    Changes in operating assets and liabilities:

     

     

     

    Inventory

     

    (11,669

    )

     

     

    (7,362

    )

    Prepaid expenses and other current assets

     

    (17,239

    )

     

     

    (6,708

    )

    Other long-term assets

     

    73

     

     

     

    (47

    )

    Accounts payable

     

    14,473

     

     

     

    3,602

     

    Accrued liabilities

     

    4,351

     

     

     

    (2,258

    )

    Deferred revenue

     

    35,480

     

     

     

    6,002

     

    Operating lease liabilities

     

    (1,182

    )

     

     

    (532

    )

    Net cash provided by operating activities

     

    109,090

     

     

     

    25,838

     

    Investing activities

     

     

     

    Purchases of investments

     

    —

     

     

     

    (70,700

    )

    Maturities of investments

     

    31,342

     

     

     

    97,700

     

    Investment in website development and internal-use software

     

    (3,711

    )

     

     

    (3,377

    )

    Purchases of property, equipment, and intangible assets

     

    (55,327

    )

     

     

    (10,581

    )

    Acquisition of business, net of cash acquired

     

    (5,100

    )

     

     

    —

     

    Net cash (used in) provided by investing activities

     

    (32,796

    )

     

     

    13,042

     

    Financing activities

     

     

     

    Proceeds from exercise of vested stock options

     

    3,928

     

     

     

    5,070

     

    Payments for taxes related to net share settlement of equity awards

     

    (25,711

    )

     

     

    (7,314

    )

    Repurchases of common stock

     

    —

     

     

     

    (28,064

    )

    Payments for debt issuance costs

     

    (1,235

    )

     

     

    —

     

    Net cash used in financing activities

     

    (23,018

    )

     

     

    (30,308

    )

    Foreign currency effect on cash and cash equivalents

     

    243

     

     

     

    2

     

    Increase in cash, cash equivalents, and restricted cash

     

    53,519

     

     

     

    8,574

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    221,440

     

     

     

    97,519

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    274,959

     

     

    $

    106,093

     

    Reconciliation of cash, cash equivalents, and restricted cash

     

     

     

    Cash and cash equivalents

    $

    273,736

     

     

    $

    105,237

     

    Restricted cash

     

    1,223

     

     

     

    856

     

    Total cash, cash equivalents, and restricted cash

    $

    274,959

     

     

    $

    106,093

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes

    $

    360

     

     

    $

    126

     

    Non-cash investing and financing activities

     

     

     

    Purchases of property and equipment included in accounts payable and accrued liabilities

    $

    11,019

     

     

    $

    594

     

    Deferred debt issuance costs included in accounts payable and accrued liabilities

     

    633

     

     

     

    —

     

    Right-of-use asset obtained in exchange for lease liability

     

    52,459

     

     

     

    2,174

     

    Issuance of common stock in connection with asset acquisition

     

    12,760

     

     

     

    —

     

    Common stock to be issued for asset acquisition indemnification holdback

     

    6,380

     

     

     

    —

     

    Non-GAAP Financial Measures

    In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

    However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

    Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net income before stock-based compensation, income taxes, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), impairment of long-lived assets, and interest income and expense, net. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

    Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income and other U.S. GAAP results.

    Net Income to Adjusted EBITDA Reconciliation

    (In Thousands, Unaudited)

     

     

    Three Months Ended March 31,

     

    2025

     

    2024

     

     

     

     

    Revenue

    $

    586,010

     

     

    $

    278,171

     

     

     

     

     

    Net income

     

    49,485

     

     

     

    11,128

     

    Stock-based compensation

     

    24,858

     

     

     

    19,032

     

    Provision for income taxes

     

    11,010

     

     

     

    1,275

     

    Depreciation and amortization

     

    8,276

     

     

     

    3,001

     

    Acquisition and transaction-related costs

     

    24

     

     

     

    376

     

    Impairment of long-lived assets

     

    —

     

     

     

    75

     

    Interest income and expense, net

     

    (2,596

    )

     

     

    (2,540

    )

    Adjusted EBITDA

    $

    91,057

     

     

    $

    32,347

     

     

     

     

     

    Net income as a % of revenue

     

    8

    %

     

     

    4

    %

    Adjusted EBITDA margin

     

    16

    %

     

     

    12

    %

    Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. "Free Cash Flow" is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

    Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.

    Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

    Net cash provided by operating activities

     

    $

    109,090

     

     

    $

    25,838

     

    Less: purchases of property, equipment, and intangible assets in investing activities

     

     

    (55,327

    )

     

     

    (10,581

    )

    Less: investment in website development and internal-use software in investing activities

     

     

    (3,711

    )

     

     

    (3,377

    )

    Free Cash Flow

     

    $

    50,052

     

     

    $

    11,880

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250505562635/en/

    Investor Relations

    Bill Newby

    [email protected]

    Media Relations

    Abby Reisinger-Moley

    [email protected]

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    8/22/2024$24.00Buy
    Needham
    8/9/2024Outperform → In-line
    Imperial Capital
    More analyst ratings

    $HIMS
    SEC Filings

    See more
    • Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/13/25 5:23:44 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/9/25 7:00:17 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Hims & Hers Health Inc.

      10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:17:34 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Introduces 6-Month Wegovy® New Customer Offer

      Hims & Hers Health, Inc. (NYSE:HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522903885/en/Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only). "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of

      5/22/25 3:39:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Him

      5/8/25 7:57:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 12:09:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Okupe Oluyemi exercised 6,437 shares at a strike of $5.01 and sold $613,537 worth of shares (11,581 units at $52.98), decreasing direct ownership by 66% to 39,153 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/30/25 4:28:11 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 4 filed by Chief Financial Officer Okupe Oluyemi

      4/A - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/29/25 5:56:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $180,628 worth of shares (3,233 units at $55.87), decreasing direct ownership by 2% to 153,194 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/29/25 5:56:14 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Citigroup with a new price target

      Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously

      1/10/25 7:53:16 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Financials

    Live finance-specific insights

    See more
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

      Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management team

      4/14/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con

      2/24/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care